Yellox

Quick links to important sections

Yellox

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yellox

What is Yellox? (Bromfenac Ophthalmic Solution)

Property Description
Active ingredient Bromfenac (as sodium sesquihydrate)
Form Ophthalmic solution (Eye drops)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Mitigation of ocular inflammation and discomfort
Origin Synthetic chemical compound
Status Prescription-only (Rx)

What is Yellox and What Class of Medicine is It?

Yellox is a prescription-only pharmaceutical preparation containing the active ingredient Bromfenac, a synthetic compound and a phenylacetic acid derivative. This medicine is classified as an Ophthalmological, Anti-inflammatory agent, non-steroid. This classification confirms the drug's core function: to reduce inflammation. Bromfenac belongs to the general therapeutic group of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a class clinically recognized for its ability to reduce inflammation and pain.


Composition and Form: The Bromfenac Ophthalmic Solution

The medication is supplied exclusively as an ophthalmic solution, packaged as sterile liquid eye drops for topical ocular use. Yellox is a single-ingredient product, containing only Bromfenac (in the form of its sodium sesquihydrate) within a sterile buffered aqueous vehicle. This specialized dosage form is a differentiating factor that avoids systemic distribution, directing the action of the Bromfenac molecule precisely to the target tissue on the eye's surface.


What is the General Purpose of Yellox?

The overall purpose of Yellox is to provide a localized, powerful anti-inflammatory effect and analgesic action within the eye. The mechanism involves the active substance blocking the cyclooxygenase (COX) enzymes, thereby suppressing the synthesis of prostaglandins, which are the chemical messengers that cause swelling, redness, and discomfort. By controlling these mediators, the general benefit is to mitigate the ocular inflammation and associated discomfort frequently observed following certain types of ocular surgery, such as cataract extraction.

What side effects are possible with Yellox?

Possible Side Effects and Safety Information

The safety profile for Yellox (Bromfenac Ophthalmic Solution) is defined by governmental regulatory documents, which categorize all reported adverse reactions based on frequency and affected physiological systems. As a topical Nonsteroidal Anti-inflammatory Drug (NSAID), its primary documented effects are concentrated in the Eye disorders system.

Frequency-Classified Adverse Reactions

The most frequently reported effects, classified as Common (occurring in 1%–8% of patients in clinical trials), include ocular symptoms such as eye pain, eye irritation (including burning/stinging), eye redness, photophobia, and blurred vision. Reactions classified as Uncommon may include corneal oedema or corneal epithelium defects.


Serious Adverse Reactions and Safety Constraints

Rare but serious adverse reactions are documented, focusing on the structural integrity of the cornea, such as corneal ulcer, corneal perforation, and scleromalacia. These events are primarily noted in post-marketing reports.

Official labeling defines specific safety constraints:

  • Duration-Related Risk: Use beyond 14 days post-surgery may increase the risk and severity of corneal adverse events.
  • Susceptible Patients: The risk of serious corneal events is elevated in patients with existing conditions like diabetes mellitus, rheumatoid arthritis, or pre-existing corneal epithelial defects.
  • Delayed Healing: As an NSAID, Yellox may slow or delay ocular wound healing, and its use in the third trimester of pregnancy should be avoided. The medicine's safety and efficacy have not been established in pediatric patients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Yellox (Bromfenac Ophthalmic Solution) provides specific guidance on over-exposure scenarios. Accidental oral ingestion of the eye drop solution is classified as presenting practically no risk of adverse effects due to systemic exposure. The total quantity of bromfenac in the bottle is documented as a minimal dose compared to former oral formulations. The mandated immediate action for ingestion is to take fluids to dilute the medicinal product.

For accidental topical overuse, the limited capacity of the conjunctival sac prevents increased exposure, and regulatory documents advise rinsing the eye with warm water.

Despite the low systemic risk, regulators warn of severe outcomes. The most serious ocular events associated with this class of topical medication are sight-threatening conditions, including corneal epithelial breakdown, ulceration, and perforation; patients must immediately discontinue use and seek close monitoring. Furthermore, the presence of sodium sulfite carries a warning regarding the potential for life-threatening anaphylactic symptoms. Urgent medical attention is required for any severe allergic symptoms, suspected ingestion, or if the individual is collapsed, mandating contact with a Poison Control Center or emergency services at once.

Therapeutic Uses of Yellox

Main uses of Yellox

Yellox is an ophthalmic solution containing bromfenac, a non-steroidal anti-inflammatory drug (NSAID). It is primarily used for the treatment of postoperative ocular inflammation in adults following cataract surgery.

When the eye undergoes surgery, such as the removal of a cloudy lens during cataract extraction, the surrounding tissues may respond with inflammation. This localized response can cause discomfort, redness, and swelling. Yellox works by inhibiting the production of prostaglandins, which are naturally occurring substances in the body that act as mediators for the inflammatory response.

Benefits of treatment

The primary benefit of using Yellox is the management and reduction of inflammation within the eye after a surgical procedure. By controlling this response, the medication helps to:

  • Reduce ocular pain: It is specifically indicated for the treatment of postoperative pain following cataract extraction.
  • Manage inflammation: It helps decrease the signs of inflammation, such as redness and swelling of the ocular tissues.
  • Support recovery: By minimizing inflammatory interference, it assists in the stabilization of the eye's environment during the healing period.

Unlike some other anti-inflammatory eye drops, Yellox does not contain steroids, making it a relevant option for patients where steroid use might be less desirable or where a non-steroidal approach is preferred by the healthcare professional.

Eligibility and Restrictions for Use

Yellox (bromfenac ophthalmic solution) is a prescription non-steroidal anti-inflammatory drug (NSAID) primarily used in adults to treat inflammation in the eye following cataract surgery. Treatment is generally limited to a period not exceeding two weeks, as safety data for longer use is unavailable.


Contraindications

Yellox must not be used by patients with:

  • A known allergy (hypersensitivity) to bromfenac, any of its inactive ingredients, or other NSAIDs (such as aspirin, diclofenac, or ibuprofen).
  • A history of asthma, urticaria (hives), or acute rhinitis that was triggered by acetylsalicylic acid (aspirin) or other medicines that inhibit prostaglandin synthesis.

Caution and Precautions

Certain patients require careful monitoring or should use Yellox with caution due to increased risk of complications. These include individuals with:

  • Bleeding disorders or those taking medications that prolong bleeding time (e.g., blood thinners).
  • Corneal issues (like dry eye syndrome or corneal epithelial defects) or those who have had complicated or repeated eye surgeries.
  • Diabetes mellitus or rheumatoid arthritis.
  • Pregnant patients, particularly during the third trimester.

Patients should not wear soft contact lenses during treatment because of the preservative (benzalkonium chloride) in the eye drops, which can be absorbed by the lenses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Yellox (Bromfenac Ophthalmic Solution) is primarily defined by its negligible systemic exposure following topical application, which minimizes the risk of systemic pharmacokinetic interactions.

Documented Interaction Patterns

Interaction Type Interacting Agent(s) Regulatory Caution/Outcome
Cross-Sensitivity Restriction Acetylsalicylic acid and other NSAIDs Contraindicated in patients with a history of asthma, urticaria, or acute rhinitis precipitated by these substances.
Pharmacodynamic Interaction Topical corticosteroids (e.g., fluorometholone, loteprednol) Co-administration may increase the potential for healing problems in ocular tissues.
Pharmacodynamic Interaction Medications that prolong bleeding time (e.g., systemic anticoagulants) Caution is needed due to the potential for ocularly applied NSAIDs to cause increased bleeding of ocular tissues (including hyphemas).
Timing-Based Rule Other topical ophthalmic medicinal products Each product must be administered at least 5 minutes apart to ensure adequate contact time and prevent wash-out.

Formal drug interaction studies investigating systemic metabolic pathways, such as those involving CYP enzymes or drug transporters, have not been performed and are not documented in regulatory labeling. Consequently, no specific interactions with food, alcohol, or herbal products are officially listed.

Mechanism of Action

Yellox operates primarily as a selective nonsteroidal anti-inflammatory drug (NSAID). Its core mechanism involves the competitive inhibition of the Cyclooxygenase-2 (COX-2) isoenzyme. Following systemic absorption, the molecule targets the active site of the COX-2 enzyme, thereby preventing the conversion of arachidonic acid into various pro-inflammatory eicosanoids, specifically prostaglandin H2 (PGH2).

This inhibition results in a significant decrease in the subsequent biosynthesis of other crucial inflammatory mediators, including prostaglandins (PGE2, PGI2) and thromboxanes (TXA2). The reduction in localized eicosanoid levels directly modulates cellular signaling pathways involved in acute inflammatory responses. At a system-level physiological consequence, this action results in the suppression of local vasodilation, edema formation, and the activity of peripheral nociceptors, maintaining the focus strictly on biochemical and systemic modulation without reference to therapeutic outcomes.

Dosage and Administration Information

How to Use Yellox

The administration of Yellox (Bromfenac Ophthalmic Solution) is strictly confined to the topical ocular route, meaning the medicine is applied directly to the surface of the eye. It is utilized for a short-term, acute course tied to the period immediately following certain ophthalmic procedures. The use protocol is standardized to ensure consistent non-systemic application.


Official Dosing and Regimen

Yellox is administered as a single drop into the affected eye(s). For the 0.9 mg/ml strength, the regimen is often specified as twice daily—once in the morning and once in the evening. The treatment protocol defines a strict duration: use typically begins the day after cataract surgery and must not exceed a total of 14 days. If a dose is missed, it should be instilled as soon as remembered, and the regular schedule should be resumed, unless the next dose is due shortly.


Population and Administration Specifics

Standard adult dosing applies to all individuals in the adult population, including the elderly. Use in the pediatric population is not established, as its safety and efficacy have not been formally studied. Key procedural constraints ensure proper use: if the patient is using more than one topical ophthalmic product, a minimum interval of five minutes is required between the instillation of Yellox and the subsequent eye drop. Patients must remove soft contact lenses before administration and may reinsert them 15 minutes later.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Yellox

Evidence Supporting Use for Postoperative Ocular Inflammation

The research into Yellox (Bromfenac Ophthalmic Solution) has primarily focused on its use in conditions associated with acute or disruptive episodes, specifically the ocular inflammation that follows surgery to remove a cataract. The foundation of this evidence is built upon multiple Randomized Controlled Trials (RCTs). These are studies research examined where patients were randomly assigned to receive either Yellox or a placebo (an inactive eye drop), often without the patient or the examining doctor knowing which was administered. These studies are relevant in trials assessing short-term or episodic symptom patterns in the post-operative period.

Researchers was studied for outcomes linked to inflammatory or irritative states over a defined time interval, typically the first one to two weeks after surgery. The outcomes measured included two main axes: the objective clearance of inflammation and the patient-reported outcomes describing perceived discomfort. The findings describe patterns observed in the studies where a larger proportion of patients reached predefined milestones for inflammation marker clearance and reported achieving a pain-free state than in the placebo groups.


Long-Term Evidence and Follow-Up Duration

Most of the primary clinical research that was studied for Yellox was designed to research exploring short-term symptom changes, aligning with the typical acute treatment period following cataract surgery. The follow-up durations in these pivotal trials were therefore limited, generally spanning only two to four weeks post-operation.

Consequently, long-term effects are not fully established by the existing core evidence base. There is limited information for long-term outcomes regarding what is known about the patterns of use associated with prolonged or repeated use. While the data contributes to understanding symptom patterns over the short term, the absence of extensive studies observing responses over defined time intervals stretching months or years means that long-term patterns associated with its use are not well-characterized.


Research Gaps and Unanswered Questions

The established evidence base is narrowly focused on inflammation following cataract extraction. The medication was not evaluated in large-scale trials for other conditions associated with acute or disruptive episodes of inflammation, such as those unrelated to surgery. Data for children are still emerging, as the safety and efficacy of Yellox have not been established in pediatric patients.

Frequently Asked Questions (FAQ)

Common questions about Yellox (FAQ)

Q: How quickly should I expect to notice a difference after using Yellox?

Studies and official information indicate that Yellox is used for a short-term, acute course following eye surgery. Clinical research examined how quickly patients experienced clearance of inflammation and reported being pain-free. These study findings described a larger proportion of patients achieving these milestones over one to two weeks of use, aligning with the typical duration of treatment.


Q: What are the official guidelines about using Yellox during pregnancy or while breastfeeding?

Official regulatory documents describe that Yellox use should be avoided during the third trimester of pregnancy. Regarding breastfeeding, it is not known whether the medicine is excreted in human milk. Official guidelines describe that a benefit/risk assessment may be considered when the medicine is used during the breastfeeding period.


Q: Can Yellox be used by people who have had previous eye surgery?

Official regulatory documents caution that certain groups of patients require careful monitoring while using Yellox. Patients with a history of complicated or repeated eye surgeries are identified as a group requiring caution due to increased risk of corneal adverse events. Regulatory caution is described for patients with a history of complicated or repeated eye surgeries.


Q: What is the purpose of the preservative in Yellox eye drops?

The solution contains a preservative, which is typically benzalkonium chloride. This ingredient is included to help keep the eye drops sterile and prevent the growth of bacteria once the bottle has been opened and used.


Q: Is the medication Yellox known to affect driving ability?

Official documents state that the medicine may cause temporary blurred vision or other visual disturbances which could affect the ability to drive or operate machinery. Official documents caution that people are advised to wait until their vision is clear before performing tasks that require visual concentration.


Q: Can Yellox be used if I am taking over-the-counter allergy eye drops?

Regulatory information specifies a timing rule for concurrent use with other topical eye products. If you are using another eye drop, including over-the-counter allergy drops, there is a required interval of at least five minutes between the administration of Yellox and the subsequent product to ensure the medicine is not washed out.


Q: Does Yellox interact with common pain relievers like Tylenol (acetaminophen)?

Yellox is a topically applied medicine, and its systemic exposure (absorption into the body) is negligible. Official regulatory documents state that formal drug interaction studies investigating systemic metabolic pathways, such as those involving acetaminophen, have not been performed and are not documented in the official labeling.


Q: Does Yellox affect blood pressure or heart medication?

The drug's interaction profile is primarily defined by its negligible systemic exposure following topical application to the eye. This action minimizes the risk of systemic pharmacokinetic interactions with most medicines taken by mouth, including heart or blood pressure medication.


Q: How long does the effect of one dose of Yellox typically last?

Yellox is an anti-inflammatory drug used for a short duration. The treatment regimen for Yellox is commonly described as a single drop administered twice daily (once in the morning and once in the evening). This frequency is determined by the product’s pharmacological properties to maintain a consistent effect over the treatment period.


Q: Is Yellox known to cause any skin reactions or rashes?

Official regulatory documents categorize all reported adverse reactions based on frequency and body system. The primary documented effects for Yellox are concentrated in the Eye disorders system. Skin reactions or rashes are not listed among the commonly or uncommonly reported side effects.


Q: Is Yellox known to cause headaches or dizziness?

Official regulatory documents categorize all reported adverse reactions based on frequency and body system. While some systemic effects can occur with medicines, headaches or dizziness are not listed among the commonly or uncommonly reported side effects for Yellox.


Q: What is meant by the 'post-marketing experience' data for Yellox?

Official product information, such as the Summary of Product Characteristics, includes data from 'post-marketing experience.' This term refers to adverse reactions or safety data that have been reported by patients or healthcare professionals after the medicine has been made available for general use in the population.


Q: What are the ingredients listed in the Yellox drops besides the active drug?

Official regulatory documents list all components of the solution. In addition to the active ingredient, Bromfenac, the drops contain inactive ingredients known as excipients. These include benzalkonium chloride (a preservative), and other substances such as boric acid, sodium borate, sodium sulfite, and purified water.


Q: Is a temporary increase in tearing or watering normal with Yellox?

Official regulatory documents list commonly and uncommonly reported ocular effects, such as pain and irritation. An increase in tearing or watering (lacrimation) is not listed among the frequently reported adverse reactions.


Q: Are there restrictions on using Yellox if I have glaucoma?

Official regulatory documentation lists several conditions that require caution, such as diabetes and rheumatoid arthritis. However, a specific restriction related to a diagnosis of glaucoma is not detailed among the listed contraindications or precautions for Yellox use in official labeling.

How should Yellox be stored and disposed of?

How to Store and Dispose of Yellox (Bromfenac Ophthalmic Solution)

Storage and disposal requirements for Yellox are defined by regulatory agencies to maintain the product’s sterility and stability.


Storage Conditions

  • Temperature: Yellox must be stored at a controlled temperature range, typically 15 C to 25 C (59 F to 77 F), and must not be stored above 25 C.
  • Handling: The eye drops must be kept from freezing and stored away from heat, moisture, and direct light.
  • Container: The bottle must be kept tightly closed when not in use. Care must be taken not to touch the dropper-tip to any surface.
  • Stability: Any unused contents must be discarded 4 weeks after first opening.
  • Child Safety: The medicine must be kept out of the reach and sight of children.

Disposal

  • Unused or expired Yellox must not be thrown away with household waste or wastewater.
  • Disposal should be carried out in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yellox found in:

A-Z Index: